GTx Q2 Loss Narrows - Quick Facts

RELATED NEWS

Trade GTXI now with

8/8/2012 6:43 AM ET

GTx Inc. (GTXI: Quote) provided a Company update and reported financial results for the second quarter of 2012.

The net loss for the second-quarter was $10.4 million or $0.17 per share compared to a net loss of $10.7 million or $0.21 per share for the same period in 2011.

Revenue for both the second quarter of 2012 and 2011 was $1.6 million and consisted of net sales of FARESTON (toremifene citrate) 60 mg, approved for the treatment of metastatic breast cancer in postmenopausal women.

Research and development expenses for the quarter were $9.2 million compared to $7.6 million for the same period in 2011.

Analysts polled by Thomson Reuters expected the company to report a loss of $0.17 per share on revenues of $2.26 million for the quarter. Analysts' estimates typically exclude special items.

GTx said it is currently enrolling subjects with advanced non-small cell lung cancer in two pivotal Phase III clinical trials, POWER 1 and POWER 2. These international Phase III studies are being conducted in clinical sites in the United States, Europe, and South America.

In each of the placebo-controlled, double-blind clinical trials, 300 patients with Stage III or IV non-small cell lung cancer are being randomized to oral daily doses of placebo or enobosarm 3 mg at the time they begin first line standard chemotherapy. Enrollment for both studies is expected to be completed in the fourth quarter of this year, and topline results should be released during the second quarter of 2013.

GTx noted that it is initiating this quarter an open-label clinical study of 75 men with metastatic castration resistant prostate cancer to test three lower doses of Capesaris (125 mg, 250 mg and 500 mg) sequentially in cohorts of 25 patients each. The Phase II 712 clinical trial is designed to assess the effect of Capesaris on serum prostate specific antigen response and prostate cancer progression.

To receive FREE breaking news email alerts for GTX Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

<<Previous 67 Articles Next>>

Editors Pick

Gap Profit Climbs 43%

Gap Inc. Thursday after the markets closed that its first quarter profit rose 43% from last year, helped by higher sales and improved margins. The company's quarterly earnings per share also came in above analysts' expectations as did its quarterly sales. At the same time, the company eaffirmed its fiscal year 2013 earnings outlook, which is below analysts' current consensus estimate.

Stocks Close Modestly Lower But Well Off Worst Levels - U.S. Commentary

After moving sharply lower at the start of trading on Thursday, stocks showed a substantial recovery attempt over the course of the trading day. The rebound came as upbeat housing data helped offset worries about the Federal Reserve. The major averages climbed well off their worst levels of the day but still ended the session in the red.

Obama Outlines Counterterrorism Policy To Confront Shifting Threats

President Barack Obama delivered a highly-anticipated speech on his administration's evolving counterterrorism policies on Thursday, suggesting that the U.S. needs to move away from a "boundless global war on terror." More than a decade after the 9/11 attacks, Obama argued that the terrorist threat has shifted and evolved.